Repare Therapeutics Inc. (RPTX)
| Previous close | 3.7900 |
| Open | 3.7500 |
| Bid | 3.5300 x 200 |
| Ask | 3.7100 x 200 |
| Day's range | 3.5200 - 3.7514 |
| 52-week range | 2.9800 - 13.8500 |
| Volume | |
| Avg. volume | 199,404 |
| Market cap | 154.926M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2300 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.33 |
Simply Wall St.Repare Therapeutics First Quarter 2024 Earnings: Beats Expectations
Repare Therapeutics ( NASDAQ:RPTX ) First Quarter 2024 Results Key Financial Results Revenue: US$52.4m (up by US$46.7m...
- Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass. & MONTREAL, May 07, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
MONTREAL & LAUSANNE, Switzerland, April 30, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial investigating lun
